Galantamine for vascular cognitive impairment

Cochrane Database of Systematic Reviews

Volumn 2006, Issue 1, 2006, Pages

  Birks, Jacqueline ^a   Craig, David ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR; GALANTAMINE; NOOTROPIC AGENT;

ALZHEIMER DISEASE; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; HUMAN; META ANALYSIS; MULTIINFARCT DEMENTIA; RANDOMIZED CONTROLLED TRIAL; REVIEW;

ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; COGNITION DISORDERS; DEMENTIA, VASCULAR; GALANTAMINE; HUMANS; NOOTROPIC AGENTS; RANDOMIZED CONTROLLED TRIALS;

EID: 33645525966     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD004746.pub2     Document Type: Review

References (42)

1. Anon. GAL-INT-26. Johnson and Johnson Pharmceutical Research and Development 26 February 2004.
2. Auchus AP, Brashear HR, Salloway S, Korczyn AD, De Deyn PP, Gassmann-Mayer C, GAL-INT-26 Study Group. Galantamine treatment of vascular dementia: a randomized trial. Neurology 2007;69(5):448-58.
3. Gassmann-Mayer C. Email author. E-mail correspondence from Dr Cristina Gassmann-Mayer. Email to: R Malouf. Email recipient 24 October 2008.
4. Bullock R, Erkinjuntti T, Lilienfeld S, GAL INT 6 Study Group. Management of patients with Alzheimer's disease plus cerebrovascular disease: 12-month treatment with galantamine. Dementia and Geriatric Cognitive Disorders 2004;17(1-2):29-34.
5. Bullock R, Lilienfeld S. Galantamine shows promising results in Alzheimer's disease with cerebrovascular components and probable vascular dementia (preliminary results). Journal of Neuroscience 2001;187(Suppl 1):S59.
6. Burke W, Lilienfeld S. Galantamine improves behaviour and relieves caregiver distress in Alzheimer's disease (AD), vascular dementia and AD with cerebrovascular disease. Proceedings of the 8th International Conference on Alzheimer's Disease and Related Disorders; 2002 July 20-25, Stockholm, Sweden 2002:Abstract No 428. 2002.
7. Erkinjuntti T. Broad therapeutic benefits in patients with probable vascular dementia or Alzheimer's disease with cerebrovascular disease after treatment with galantamine. European Journal of Neurology 2002;9(5):545.
8. Erkinjuntti T, Gauthier S, Bullock R, Kurz A, Hammond G, Schwalen S, et al.Galantamine treatment in Alzheimer's disease with cerebrovascular disease: Responder analyses from a randomized, controlled trial (GAL-INT-6). Journal of Psychopharmacology 2008;22(7):761-8.
9. Erkinjuntti T, Kurz A, Gauthier S, Bullock R, Lilienfeld S, Damaraju CV. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Lancet 2002;359(9314):1283-90.
10. Erkinjuntti T, Kurz A, Small GW, Bullock R, Lilienfeld S, Damaraju CV. An open-label extension trial of galantamine in patients with probable vascular dementia and mixed dementia. Clinical Therapeutics 2003;25(6):1765-82.
11. Erkinjuntti T, Lilienfed S. Cognitive benefits with 12 months of galantamine treatment in patients with Alzheimer's disease and concomitant cerebrovascular disease (mixed dementia). Proceedings of the 8th International Conference on Alzheimer's Disease and Related Disorders; 2002 July 20-25, Stockholm, Sweden 2002:Abstract No 446. 2002.
12. Erkinjuntti T, Lilienfeld S, Damaraju CV. Long-term treatment with galantamine is effective in slowing cognitive decline in patients with probable vascular dementia. Proceedings of the 7th International Geneva/Springfield Symposium on Advances in Alzheimer therapy, Apr 3-6, Geneva 2002:181. 2002.
13. Kertesz A. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomized trial. Current Neurology & Neuroscience Reports 2002;2(6):503-4.
14. Kurz A. Non-cognitive benefits of galantamine (Reminyl(R)) treatment in vascular dementia. Acta Neurologica Scandinavica 2002;106(178 Suppl):19-24.
15. Kurz A, Lilienfeld S, Damaraju CV. Galantamine is safe and effective for the long-term treatment of cognitive decline in patients with Alzheimer disease with cerebrovascular components or probable vascular dementia. Proceedings of the 7th International Geneva/Springfield Symposium on Advances in Alzheimer therapy, Apr 3-6, Geneva 2002:206. 2002.
16. Kurz AF, Erkinjuntti T, Small GW, Lilienfeld S, Damaraju CR. Long-term safety and cognitive effects of galantamine in the treatment of probable vascular dementia or Alzheimer's disease with cerebrovascular disease. European Journal of Neurology the official journal of the European Federation of Neurological Societies 2003;10(6):633-40.
17. Small G, Erkinjuntti T, Kurz A, Lilienfeld S. Galantamine in the treatment of cognitive decline in patients with vascular dementia or Alzheimer's disease with cerebrovascular disease. CNS drugs 2003;17(12):905-14.
18. Senanarong V, Poungvarin N, Phanthumchinda K, Tavichachart N, Chankrachang S, Praditsuwan R, et al.Tolerability study of galantamine in possible Alzheimer's disease with or without cerebrovascular disease; a slow-titration regimen in Thai patients. 8th Congress of the European Federation of the Neurological Sciences. Paris, France. September 4-7. 2004.
19. Thavichachart N, Phanthumchinda K, Chankrachang S, Praditsuwan R, Nidhinandana S, Senanarong V, et al.Efficacy study of galantamine in possible Alzheimer's disease with or without cerebrovascular disease; a slow-titration regimen in Thai patients. 8th Congress of the European Federation of the Neurological Sciences. Paris, France. September 4-7. 2004.
20. Small GW, Ekinjuntti T, Kurz A, Lilienfeld S. Galantamine in the treatment of cognitive decline in patients with vascular dementia or Alzheimer's disease with cerebrovascular disease. CNS Drugs 2003;17:905-14.
21. Chui H, Victoroff J, Margolin D, Jagust W, Shankle R, Katzman R. Criteria for the diagnosis of ischemic vascular dementia proposed by the State of California Alzheimer's Disease Diagnostic and Treatment Centers. Neurology 1992;42(3 Part 1):473-80.
22. Cummings JL. Frontal-subcortical circuits and human behavior. Archives of Neurology 1993;50(8):873-80.
23. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2308-14.
24. Erkinjuntti T, Inzitari D, Pantoni L, Wallin A, Scheltens P, Rockwood K, et al.Research criteria for subcortical vascular dementia in clinical trials. Journal of Neural Transmission 2000;59(Supplement):23-30.
25. Galasko D, Bennett D, Sano M, Ernesto C, Thomas R, Grundman M, et al.An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer's Disease and Associated Disorders 1997;11 Suppl 2:S33-9.
26. Gelinas I, Gauthier L, McIntyre, M. Development of a functional measure for persons with Alzheimer's disease: the Disability Assessment for Dementia. American Journal of Occupational Therapy 1999;53:471-81.
27. Knopman DS, Knapp MJ, Gracon SI, Davis CS. The Clinician Interview Based Impression (CIBI): a clinician's global change rating scale in Alzheimer's disease. Neurology 1994;44:2315-21.
28. Lilienfeld S. Galantamine: a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease. CNS Drug Reviews 2002;8(2):159-76.
29. Malouf R, Birks J. Donepezil for vascular cognitive impairment. Cochrane Database of Systematic Reviews 2004, Issue 1. [DOI: 10.1002/14651858.CD004395.pub2].
30. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Sciences Task Force on Alzheimer's disease. Neurology 1984;34:939-44.
31. MRC CFAS, Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS). Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. The Lancet 2001;357:169-75.
32. O'Brien J, Perry R, Barber R, Gholkar A, Thomas A. The association between white matter lesions on magnetic resonance imaging and noncognitive symptoms. Annals of the New York Academy of Sciences 2000;903:482-9.
33. O'Brien JT, Erkinjuntti T, Reisberg B, Roman G, Sawada T, Pantoni L, et al.Vascular cognitive impairment. The Lancet Neurology 2003;2:89-98.
34. Perry E, Kay DW. Some developments in brain ageing and dementia. British Journal of Biomedical Science 1997;54(3):201-15.
35. Perry E, Ziabreva I, Perry R, Aarsland D, Ballard C. Absence of cholinergic deficits in "pure" vascular dementia. Neurology 2005;64:132-3.
36. Pohjasvaara T, Mantyla R, Ylikoski R, Kaste M, Erkinjuntti T. Clinical features of MRI-defined subcortical vascular disease. Alzheimer's Disease and Associated Disorders 2003;17(4):236-42.
37. Roman G, Tatemichi T, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, et al.Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993;43(2):250-60.
38. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. American Journal of Psychiatry 1984;141(11):1356-64.
39. Royall DR, Mahurin RK, Gray KF. Bedside assessment of executive cognitive impairment: the executive interview. Journal of the American Geriatrics Society 1992;40(12):1221-6.
40. Toghi H, Abe T, Kimura M, Saheki M, Takahashi S. Cerebrospinal fluid acetylcholine and choline in vascular dementia of Binswanger and multiple small infarcts types as compared with Alzheimer-type dementia. Journal of Neural Transmission 1996;103:1211-20.
41. World Health Organization. International classification of diseases, 10th revision. Geneva: World Health Organization, 1992.
42. Craig D, Birks J. Galantamine for vascular cognitive impairment. Cochrane Database of Systematic Reviews 2006, Issue 1. [DOI: 10.1002/14651858.CD004746.pub2].